Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Board fully replaced NBB
No director from three years ago is still active according to annual account 2025.
Financials
Financial year 2025
Swiftpharma from Genk, company number BE0781598284, closed financial year 2025 with a result of € -1.8 million after tax. For that financial year Swiftpharma recorded a gross margin of € -22,099 and equity of € 834,755. Compared with financial year 2024, the result moved from € -1.9 million to € -1.8 million. The company made a loss. The buffer shrank hard: equity is 68 % below last year. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on April 27, 2026.
€ 834,755
▼ 68% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -1.8 million
▲ 7 % less loss than in 2024
Profit after tax over the fiscal year.
€ 433,880
▼ 67% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -3.6 million.
People and assets in 2025
12.3
▲ 9.5 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1.2 million
▲ € 974,118 vs 2024
€ 96,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 46,923
▲ 160% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 3.5 million
▲ 254% vs 2024
Loans from banks and other lenders, long and short.
€ 371,553
▼ 68% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 92,224
▲ 41% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Gross margin | € 331,174 | € -1,382,412 | € -22,099 | ▲ € 1.4 million |
| Profit after taxes | € 57,060 | € -1,883,926 | € -1,750,880 | ▲ € 133,047 |
| Equity | € 59,560 | € 2,585,634 | € 834,755 | ▼ 68% |
| Total debts | € 1,067,460 | € 2,247,030 | € 4,063,275 | ▲ 81% |
| Cash | € 91,324 | € 1,307,910 | € 433,880 | ▼ 67% |
| Retained profit | € 57,060 | € -1,826,866 | € -3,577,745 | ▼ € 1.8 million |
| Bank debt | € 580,000 | € 1,000,000 | € 3,536,861 | ▲ 254% |
| Balance sheet total | € 1,127,021 | € 4,832,664 | € 4,898,030 | ▲ 1% |
| Employees (FTE) | 1 | 2.8 | 12.3 | ▲ 9.5 |
Key figures of Swiftpharma, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Swiftpharma?
What happened at Swiftpharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 1.8 million. Source: NBB ↗
- Bart Goddyn stepped down as director. NBB
- Bart Goddyn became a director. NBB
- JVHealth BV stepped down as director. NBB
- HofMan BV became a director. NBB
- Raymond Perrenet became a director. NBB
- New establishment in Genk. KBO
- Start of the company according to the CBE. KBO
In short
From € 57,060 profit in 2023 to € 1.8 million loss in 2025.
Paid € 5,401 in corporate taxes since 2023.
Best year ever: 2023, with € 57,060 profit.
On average € 331,200 of value added per employee in 2023.
A new publication or filing at Swiftpharma? We notify you, reason included.
Follow SwiftpharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of ASTERION RESEARCH & DEVELOPMENT comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
SwiftpharmaBehind Swiftpharma are Raymond Perrenet and HofMan BV. The shares are held by ASTERION RESEARCH & DEVELOPMENT (52.8%).
Directors
According to the 2025 annual accounts
Raymond Perrenet
Director
since 2024
Director · represented by Hofenk Jeroen
since 2024
since 2025 · until 2025
Director · represented by Van Havermaet Johan
since 2022 · until 2025
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Thor Park 8027 box /0215
3600 Genk
Thor Park 8027 box 215
3600 Genk
Active since 4 February 2022
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.
All companies at this address →MACO
€ 1.1 million gross margin · 2025
Greensoil Group
€ 1.5 million gross margin · 2025
Hyve
€ 1.1 million gross margin · 2025
Boolean
€ 214,953 gross margin · 2025
VIMANPRO
€ 58,083 gross margin · 2025
+1 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0781.598.284
- VAT number
- BE 0781.598.284
- Registered office
- Thor Park 8027 bus /0215, 3600 Genk
- Names & denominations
- Swiftpharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 4 February 2022
- Peppol
- Active · Active since 27 Feb 2025
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Groothandel in farmaceutische en medische artikelen
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Markt- en opinieonderzoek
Vervaardiging van farmaceutische grondstoffen